Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodofalan I-131 - Telix Pharmaceuticals

Next Previous
Drug Profile

Iodofalan I-131 - Telix Pharmaceuticals

Alternative Names: 124I-ACD-101; 124I-TX-101; 131I TLX101; 131I-ACD-101; 131I-IPA; 131I-TX-101; 131I-iodofalan; 131I-IPA - Telix Pharmaceuticals; ACD-101; Iodofalan-I-131 - Telix Pharmaceuticals; TLX-101; TLX101-Tx; TX-101

Latest Information Update: 28 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapeia
  • Developer Telix Pharmaceuticals; Therapeia
  • Class Amino acids; Antineoplastics; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Apoptosis stimulants; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma

Most Recent Events

  • 28 May 2026 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, First-line therapy) in Australia (IV, Infusion)
  • 28 May 2026 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, First-line therapy) in Austria (IV, Infusion)
  • 28 May 2026 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, First-line therapy) in Netherlands (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top